fda approval for tirzepatide Eli Lilly Gets Zepbound for Certain Sleep Apnea Patients Yesterday the FDA approved tirzepatide

Lifestyle Factors Still Matter Retatrutide may support weight loss, but factors such as nutrition, sleep, stress, and physical activity continue influencing outcomes

However, it is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those who are pregnant or breastfeeding

Temporary tingling or numbness in extremities affects 15-20% of users, usually resolving after 3-4 weeks

It's crucial to know that these side effects are typically mild to moderate

Jornal Brasileiro de Patologia e Medicina Laboratorial

The SUSTAIN-6 trial showed reduced risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease